【ファイザーについて】
Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for a booster shot of the Pfizer-BioNTech COVID-19 vaccine in certain populations and also recommended a booster dose for those in high risk occupational and institutional settings.
対象となる人
CDC recommends:
-
people 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
-
people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
-
people aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and
-
people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.
Occupations at increased risk for COVID-19 exposure and transmission include front line essential workers and health care workers as previously detailed by the CDC [ 1 ]
- First responders (healthcare workers, firefighters, police, congregate care staff)
- Education staff (teachers, support staff, daycare workers)
- Food and agriculture workers
- Manufacturing workers
- Corrections workers
- U.S. Postal Service workers
- Public transit workers
- Grocery store workers
1 List could be updated in the future
【モデルナ】
We (CDC) will also evaluate with similar urgency available data in the coming weeks to swiftly make additional recommendations for other populations or people who got the Moderna or Johnson & Johnson vaccines.
ただし、免疫不全の方に関しては二回目の接種から28日たっていれば三回目を打てます(ファイザーと同じ条件)。
【J&J (ヤンセン)】
【インフルエンザワクチンとの同時接種】
【COVID関連最近話題のニュース】
Vaccine mandate vs Job position
COVID治療薬第三相試験で明るい兆し!
上向きのニュースもありますよ!
メルク
メルクは第三相試験 (治験の最終段階) で治験対象のmolnupiravir (日本語ではモルヌピラビルとでもなるのか?) が入院や死亡リスクを50%程度減少させる結果を得たことから、FDAの緊急承認を申請する見通し。
申請が通れば、COVIDにたいする初めての経口治療薬となる予定。www.cnbc.com
塩野義製薬
日本でも塩野義製薬が年内承認申請を目指して、最終段階の第三相へ。www.nikkei.com塩野義は大学の同胞・先輩後輩も多く働いていて希少疾患とかもかなり力入れているし良いイメージだからめっちゃうまくいってほしい!!ワクチンでかなり出遅れた日本、ここで承認に是非漕ぎついてほしい!!
メルクはばんばん会社買収吸収してデカすぎだから
なんか、うん、ほんとシオノギ応援してます!
では今日はこの辺で。
ここまで読んでいただきありがとうございました。
よろしければ励みになりますのでクリックをお願いいたします♡